Clinical Trial Update: Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating a triplet of Fruquintinib, Sintilimab, and the CAPEOX chemotherapy regimen as first-line therapy for metastatic gastroe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Capecitabine (capecitabine)
• Fruquintinib (fruquintinib)
• OXALIPLATIN (Oxaliplatin)
• Sintilimab (sintilimab)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Metastatic Gastroesophageal Junction Adenocarcinoma | Phase 1, Phase 2 | Status: RECRUITING